Alligator cancer therapy-arkiv - BioStock

Alligator to maximise immuno-oncology innovation

Alligator to maximise immuno-oncology innovation

27 March, 2024

Clinical effects Alligator's bispecific 4-1bb agonist

Clinical effects observed with Alligator’s 4-1BB agonist

14 March, 2024

Alligator prepares for phase III with CD40 agonist

Alligator prepares for phase III with CD40 agonist

20 February, 2024

SørenBregenholt, CEO AlligatorBioscience

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

31 January, 2024

AlligatorBoldVision

Alligator showcases bold drug development vision

8 December, 2023

Alligator_Strong_Q3

Strong Q3 performance for Alligator Bioscience

2 November, 2023

Interview with Alligators's CEO from LSX in Copenhagen

Alligator’s CEO: trust is a key to success

12 October, 2023

Alligator Biosciece presents mitazalimab data

Data backs up anti-tumour effect of Alligator’s lead asset

5 October, 2023

Alligator orphan designation EMA

Alligator Bioscience expands orphan designation to Europe

30 August, 2023

Alligator orphan drug designation

Alligator Bioscience awarded Orphan Drug Designation for mitazalimab

25 May, 2023

12 Page 1 of 2